TABLE 2.
ELISA reactivity of B. microti recombinants rBMN1-2, -15, and -17 and rMN-10 with sera from individuals with B. microti infections, Lyme disease, HGE, or coinfections as well as from random donors
| Antigen | ELISA resulta
|
||||
|---|---|---|---|---|---|
| Infection serum panel (IFA positive)
|
Controls (random normal donors) | ||||
|
Babesia positive
|
Babesia negative
|
||||
| Babesia | Babesia-Ehrlichia | Ehrlichia | Lyme disease agent | ||
| BMN1-2 | 27/40 | 2/3 | 1/4 | 0/10 | 1/73 |
| BMN1-15 | 31/41 | 3/3 | 0/4 | 1/10 | 0/40 |
| BMN1-17 | 33/40 | 3/3 | 0/4 | 0/10 | 0/86 |
| MN-10 | 31/39 | 3/3 | 0/4 | 1/10 | 1/98 |
| BMN1-17–MN-10 | 39b/40 | 3/3 | 0/4 | 1/10 | 1/98 |
a
Data are shown as number of ELISA-positive samples/total number of IFA-positive samples. The cutoff for the assays was determined from the mean of the normal random donor population plus 3 standard deviations of the mean.
b
One sample that was not detected, Bm22, is a resolved, transfusion-acquired infection sample which was PCR negative at the time of collection and had a low IFA titer (1:128).